GOSS Gossamer Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1728117 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-58.0%
TTM net income YoY-71.6%
TTM EPS YoY-221.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-361.9%
Net margin-344.8%
FCF margin-383.7%
EBITDA margin-361.1%
Returns
ROE-783.4%
ROA-45.2%
ROIC (approx.)—
Asset turnover0.13x
Leverage & solvency
Liabilities / assets119.1%
Debt / equity—
Current ratio4.40x
Interest coverage-13.28x
Cash quality & payout
Operating cash flow / net income1.11x
Accruals ratio5.1%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $38.43M | $9.24M | $16.95M | $13.80M | $13.29M | $11.49M | $9.89M | $9.38M |
| R&D expense | $18.83M | $26.41M | $43.08M | $48.94M | $45.54M | $41.58M | $38.04M | $36.11M |
| SG&A expense | $9.64M | $8.90M | $18.75M | $10.90M | $9.39M | $8.68M | $8.66M | $9.39M |
| Operating income | $7.20M | -$26.07M | -$44.87M | -$46.04M | -$49.11M | -$38.77M | -$36.81M | -$36.13M |
| Interest expense | $2.46M | $2.71M | $2.75M | $2.75M | $2.75M | $2.74M | $2.75M | $2.74M |
| Pretax income | — | — | — | -$47.33M | -$48.22M | -$38.27M | — | -$35.44M |
| Income tax | — | — | — | -$88,000 | $0 | $0 | — | -$2.41M |
| Net income | -$48.07M | $16.90M | -$46.66M | -$47.24M | -$48.22M | -$38.27M | -$36.64M | -$33.03M |
| EBITDA | $7.20M | -$26.07M | -$44.86M | -$46.03M | -$49.11M | -$38.76M | -$36.80M | -$36.02M |
| EPS (basic) | -7.36 | 0.05 | -0.20 | — | -16.92 | -0.17 | -0.16 | — |
| EPS (diluted) | -7.36 | -0.08 | -0.20 | — | -16.92 | -0.17 | -0.16 | — |
| Weighted avg. shares (diluted) | 6.53M | 328.78M | 234.14M | — | 2.85M | 227.28M | 226.82M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $51.19M | $41.15M | $41.03M | $37.73M | $8.93M | $26.31M | $29.02M | $46.07M |
| Short-term investments | $0 | $15.88M | $58.19M | $99.20M | $171.29M | $186.61M | $228.91M | $248.44M |
| Receivables | $0 | $6.11M | $9.25M | $12.23M | $9.24M | $7.58M | $6.58M | $5.34M |
| Current assets | $60.43M | $72.72M | $124.54M | $167.64M | $203.99M | $235.90M | $275.48M | $309.89M |
| PP&E, net | $51,000 | $55,000 | $59,000 | $64,000 | $70,000 | $76,000 | $29,000 | $10,000 |
| Total assets | $64.34M | $76.87M | $128.90M | $172.25M | $208.82M | $240.93M | $280.59M | $315.29M |
| Current liabilities | $99.94M | $137.78M | $56.51M | $63.44M | $62.12M | $53.59M | $48.22M | $45.01M |
| Short-term debt | — | — | — | — | — | — | — | $0 |
| Long-term debt | — | — | — | — | — | — | — | $0 |
| Total debt | — | — | — | — | — | — | — | $0 |
| Total liabilities | $187.13M | $170.90M | $290.38M | $295.01M | $291.15M | $287.03M | $286.84M | $285.80M |
| Shareholders' equity | -$122.80M | -$94.03M | -$161.48M | -$122.76M | -$82.33M | -$46.11M | -$6.25M | $29.49M |
| Net debt | — | — | — | — | — | — | — | -$46.07M |
| Shares outstanding | 6.12M | 488.85M | 234.70M | 2.92M | 231.31M | 227.32M | 227.22M | 226.60M |
| Cash flow statement | ||||||||
| Operating cash flow | -$29.58M | -$39.42M | -$38.72M | -$48.31M | -$36.17M | -$47.06M | -$39.72M | -$35.48M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 | $53,000 | $26,000 | $0 |
| Free cash flow | -$29.58M | -$39.42M | -$38.72M | -$48.31M | -$36.17M | -$47.11M | -$39.75M | -$35.48M |
| Investing cash flow | $15.90M | $42.70M | $41.61M | $73.16M | $17.01M | $44.13M | $22.06M | $53.22M |
| Financing cash flow | $23.72M | -$3.14M | $512,000 | $3.96M | $1.87M | $94,000 | $504,000 | $0 |
| Depreciation & amortization | $4,000 | $4,000 | $5,000 | $6,000 | $6,000 | $6,000 | $6,000 | $108,000 |
| Stock-based compensation | $3.79M | $2.46M | $6.30M | $2.90M | $2.67M | $2.59M | $2.40M | $4.96M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.